According to results of a comparative clinical trial published in the New England Journal of Medicine, VV116 is as effective as Paxlovid at curbing mild to moderate illness
China’s abandoning Zero-COVID also meant abandoning any tracking of real figures in terms of case counts and deaths. Estimates, however, provide a horrific account of the public health crisis sweeping across the country.